Virbac (CHIX:VIRPP) Issuance of Debt: €159 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VIRPP Virbac SA CHIX:VIRPP
87 GF Score
Price €336.75
GF Value €352.82
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Virbac Issuance of Debt?

Virbac CHIX:VIRPP 87 Issuance of Debt is €159 Mil as of Dec. 2025. GuruFocus rates CHIX:VIRPP with a GF Score™ of 87/100 and a GF Value™ of €352.82 (Fairly Valued). The stock has 2 warning signs investors should review.

Virbac's Issuance of Debt for the six months ended in Dec. 2025 was €70 Mil.

Virbac's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was €159 Mil.

Virbac Issuance of Debt Related Terms

Virbac Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Virbac's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Issuance of Debt Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.64 85.44 88.65 273.63 159.39

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.17 321.73 -48.10 89.63 69.75
CHIX:VIRPP
87GF Score
Virbac SA CHIX:VIRPP
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €159 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of €159 Mil mean?
Virbac (CHIX:VIRPP) has a Issuance of Debt of €159 Mil as of Dec. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Virbac and its competitors.
Is Virbac's Issuance of Debt too high?
Virbac's current Issuance of Debt is €159 Mil. Overall, Virbac has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virbac's Issuance of Debt compare to LLY and JNJ?
Virbac's Issuance of Debt of €159 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Drug Manufacturers company?
A good Issuance of Debt depends on the Drug Manufacturers industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Virbac and its competitors. Virbac's current Issuance of Debt is €159 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (CHIX:VIRPP) is currently considered Fairly Valued. The stock's GF Value™ is €352.82, compared to a current price of €336.75 — trading 4.6% below its estimated fair value. The current Issuance of Debt is €159 Mil. Virbac's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Issuance of Debt is €159 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €336.75 is trading 4.6% below its estimated GF Value™ of €352.82. GuruFocus considers Virbac to be Fairly Valued.

Key valuation signals for CHIX:VIRPP:

  • Issuance of Debt: €159 Mil
  • GF Value™: €352.82 vs. price of €336.75 (4.6% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
87GF Score

Get the complete analysis for CHIX:VIRPP

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€336.75
Price
€352.82
GF Value